Business Wire

More Than Half of Physicians Have Been Asked By Patients for an Unapproved COVID-19 Treatment

Share

A new survey from Sermo, a physician-first online community and leader in global HCP insights, found that physicians are facing a challenging onslaught of COVID-19 vaccine and treatment misinformation as reported by 3,600+ doctors around the world.

81% of physicians reported feeling that social media misinformation has caused an existential crisis in their profession. More than half (54%) of physicians surveyed reported that a patient has asked them for an unapproved COVID-19 treatment such as Ivermectin and Hydroxychloroquine. Also, more than half (55%) of physicians reported that COVID-19 vaccine misinformation is increasingly becoming an issue when meeting with patients.

Physicians are being bombarded with a variety of COVID-19 vaccine misinformation. The most common misinformation they are hearing from patients is that vaccine safety and effectiveness cannot be trusted because researchers rushed the development of the vaccine, reported by 60% of physicians.

Other types of misinformation heard by physicians from patients include:

  • More than half (51%) of physicians reported hearing from patients that they don’t need a COVID-19 vaccine if they’ve already had Covid.
  • Misinformation about vaccines modifying your DNA continues to prevail. 45% of physicians reported hearing this from patients.
  • Conspiracy theories about microchips in vaccines have made their way to the doctor’s office as 29% of physicians reported hearing this from patients.
  • 1 in 5 (20%) physicians reported hearing from patients that the COVID-19 vaccine gives you COVID-19.
  • One-third of physicians (34%) reported hearing from patients that vaccines cause infertility. Physicians feel that vaccine hesitancy among pregnant women persists. 61% of physicians reported that pregnant patients are reluctant to get the vaccine.
  • COVID-19 vaccine hesitancy is spilling over to other vaccines. 52% of surveyed physicians feel patients who have been hesitant to get COVID-19 vaccines will stop getting other vaccines.

“It’s clear from when we first launched the COVID-19 barometer at the start of the pandemic that misinformation is increasingly posing huge challenges to physicians when treating patients. Physicians feel like they are battling an infodemic that is threatening public health,” says Peter Kirk, Sermo CEO. “The barometer results clearly paint a picture that misinformation is showing up at appointments across the U.S. and the globe at a very local level.”

In addition to battling COVID-19 misinformation, surveyed physicians continue to report they are seeing a significant amount of reluctance among parents to get their kids vaccinated. 61% of physicians reported seeing patients more reluctant to vaccinate their children than themselves. Lack of long-term vaccine safety data in children (45%) was the leading reason physicians believed parents were reluctant to vaccinate their children. This is an increase from a previous Barometer survey fielded in November 2021 when 38% of physicians believed that lack of long-term vaccine safety data was keeping parents from vaccinating their children. 1 in 4 (23%) physicians believed that adverse effects and allergic reactions were a reason that parents weren’t vaccinating their children.

This survey was fielded as part 22 of Sermo’s COVID-19 Barometer and included more than 3,600 physician respondents between March 2 - March 3, 2022. To find out more about the findings of Sermo’s latest COVID-19 Real Time Barometer, visit app.sermo.com/covid19-barometer.

About Sermo:

Sermo turns physician experience, expertise, and observations into actionable insights for the global healthcare community. Engaging with more than 1.3 million HCPs across 150 countries, the company provides physicians with a social platform and unique community that fosters impactful peer-to-peer collaboration & discussions about issues that are important to them and their patients. Sermo offers on-demand access to physicians via a suite of proprietary technology to provide business intelligence that benefits pharmaceutical, healthcare partners, and the medical community at large. To learn more, visit www.sermo.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Erin Fitzgerald
pr@sermo.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Global CIOs geared up to scale AI but organizations aren’t as ready25.4.2024 05:00:00 CEST | Press release

AI is the CIO’s top priority, according to findings of Lenovo’s third annual global CIO report. Inside the Tornado: How AI is Reshaping Corporate IT Today, reveals that while CIOs need to adopt and scale AI urgently, their ambitions are threatened by speed, security, and other organizational functions lagging in AI readiness. In a stark contrast to previous years, CIOs are tabling non-traditional responsibilities to sharpen their focus on core IT functions. Slightly more than half (51%) of CIOs feel AI/ML is an urgent priority to address, matched only by cybersecurity. This urgency is directly correlated to the pressure that CIOs are under to drive business impact, rather than operational maintenance and preservation. 84% of CIOs revealed they are being evaluated on business outcome metrics more than ever before. “Today’s CIOs are working in a tornado of innovation. After years of IT expanding into non-traditional responsibilities, we’re now seeing how AI is forcing CIOs back to their

Mundipharma acquires all assets and rights related to REZZAYO ® (rezafungin) , reinforcing continued commitment to management of infectious diseases and specialty care therapeutic area24.4.2024 22:01:00 CEST | Press release

Mundipharma* today announced the acquisition of all assets and rights related to rezafungin globally from Cidara Therapeutics. This provides Mundipharma with global ownership of rezafungin including ongoing development and distribution. Rezafunginis a novel once-weekly echinocandin indicated for the treatment of invasive candidiasis in adults.1 Invasive candidiasis, is a severe, life-threatening infection of the bloodstream and/or deep/visceral tissues.2,3 It affects seriously ill people, especially those with a weakened immune systemand the mortality rate can be 40%4 or more.5,6 It can place a large burden on the healthcare system, with the potential for extended treatment regimens and long hospital stays.6 Over the last 15 years, there have been no new treatments and morbidity and mortality rates remain largely the same, indicating the need for alternative treatment options.7,8 “This acquisition places Mundipharma in the best position to realise the full potential of rezafungin inclu

Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting24.4.2024 22:01:00 CEST | Press release

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share research outcomes from its broad hematology and solid tumor portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31 - June 4, 2024. “Our presentations at this year’s ASCO highlight the strength of our growing oncology portfolio and our commitment to developing treatments that address the unmet needs of patients with B-cell malignancies and solid tumors,” Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology at BeiGene. “The exciting data we will share during ASCO showcase BRUKINSA’s uniquely differentiated clinical profile and add to the growing body of evidence supporting its role across the blood cancer treatment paradigm.” BeiGene will share new data for BRUKINSA (zanubrutinib), which add to the robust efficacy and safety evidence differentiating it within the BTK class. Key highlights include: A network meta-analysis co

TSMC Celebrates 30 th North America Technology Symposium with Innovations Powering AI with Silicon Leadership24.4.2024 21:30:00 CEST | Press release

TSMC (TWSE: 2330, NYSE: TSM) today unveiled its newest semiconductor process, advanced packaging, and 3D IC technologies for powering the next generation of AI innovations with silicon leadership at the Company’s 2024 North America Technology Symposium. TSMC debuted the TSMC A16TM technology, featuring leading nanosheet transistors with innovative backside power rail solution for production in 2026, bringing greatly improved logic density and performance. TSMC also introduced its System-on-Wafer (TSMC-SoW™) technology, an innovative solution to bring revolutionary performance to the wafer level in addressing the future AI requirements for hyperscaler datacenters. This year marks the 30th anniversary of TSMC’s North America Technology Symposium, and more than 2,000 attended the event, growing from less than 100 attendees 30 years ago. The North America Technology Symposium in Santa Clara, California kicks off TSMC Technology Symposiums around the world in the coming months. The symposiu

Rimini Street Appoints Steve Hershkowitz as Chief Revenue Officer24.4.2024 18:50:00 CEST | Press release

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, products, and services, the leading third-party support provider for Oracle and SAP software, and a Salesforce and AWS partner, today announced the appointment of Steve Hershkowitz as its new Chief Revenue Officer (CRO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240424061249/en/ Rimini Street Appoints Steve Hershkowitz as Chief Revenue Officer (Photo: Business Wire) “Steve’s leadership and extensive experience scaling businesses to deliver top-line growth will expand our sales reach to capture new logos and increase our opportunity to provide even greater value to our clients,” said Rimini Street president and CEO Seth Ravin. “The global revenue team and I are excited to work closely together with Steve to drive growth and broader capabilities for our company.” Leading the Next Chapter of Sales Growth and Continued Success f

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye